文献速递乳腺癌放疗放疗物理与技术

乳腺癌患者接受乳房切除术后均匀扫描质子治疗的早期结局

Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy.
PubMed 文献 · Radiother Oncol · 2018-11-07

单质子中心2013年12月至2015年2月连续纳入42例非转移性乳腺癌乳房切除术后患者,接受胸壁及区域淋巴结辅助质子治疗,中位随访35个月,3年局部区域无病生存率96.3%、无转移生存率84.1%、总生存率97.2%,全部急性皮肤毒性为1或2级。

要点

  • 42例患者中位随访35个月,3年局部区域无病生存率96.3%、无转移生存率84.1%、总生存率97.2%。
  • 全部患者发生1或2级急性皮肤毒性,无3或4级急性皮肤毒性。
  • 中位PTV V95超过95%,中位平均心脏剂量小于1 Gy(RBE)。

核心结论

  • 中位随访接近三年,乳房切除术后质子放疗显示出优异的局部区域控制率和良好的毒性特征。
  • 心脏保护性放疗的长期不良反应需要更长的随访时间和随机临床试验。

研究设计与样本

  • 单质子中心回顾性报告,2013年12月至2015年2月连续纳入42例因非转移性乳腺癌接受乳房切除术的患者,术后接受胸壁及区域淋巴结辅助质子治疗,采用3D适形均匀扫描和对穿匹配野。

主要发现

  • 中位随访35个月(范围1-55个月),1例局部失败、0例区域淋巴结失败、6例远处失败。
  • 3年局部区域无病生存率96.3%,无转移生存率84.1%,总生存率97.2%。
  • 唯一局部失败事件发生于放疗完成后约2.5年,位于放疗野内胸壁。
  • 皮肤皮炎、乏力和食管炎是最常见的急性毒性,全部患者发生1或2级急性皮肤毒性,无3或4级急性皮肤毒性。
  • 中位PTV V95超过95%,中位平均心脏剂量小于1 Gy(RBE)。

关键数值与推荐

  • 3年局部区域无病生存率96.3%,3年无转移生存率84.1%,3年总生存率97.2%。
  • 中位PTV V95超过95%,中位平均心脏剂量小于1 Gy(RBE)。
  • 全部患者发生1或2级急性皮肤毒性,无3或4级急性皮肤毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出心脏保护性放疗的长期不良反应需要更长的随访时间和随机临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postmastectomy proton radiotherapy improves normal tissue sparing in comparison to photon-based approaches. Several studies have reported dosimetry comparison and tolerable acute toxicity profile with limited follow-up. We report our institutional experience of postmastectomy proton radiation including clinical efficacy and toxicities. METHODS: From December 2013 to February 2015, 42 consecutive patients who received mastectomy for non-metastatic breast cancer were treated with adjuvant chest wall and regional nodal proton therapy at a single proton center. 3D conformal uniform scanning with en face matching fields was used. RESULTS: The median follow-up among patients was 35 months (range 1-55 months). There was one local failure, zero regional nodal failure, and six distant failures. The 3-year rate of locoregional disease-free survival was 96.3%, metastasis-free survival was 84.1%, and overall survival was 97.2%. The only local failure event occurred on the chest wall within the radiation field, approximately 2.5 years after the completion of radiation. Skin dermatitis, fatigue, and esophagitis were the most common acute toxicity. All patients developed grade 1 or 2 acute skin toxicity and there was no grade 3 or 4 acute skin toxicity. Proton radiation is able to achieve excellent target coverage with median PTV V95 over 95% and heart sparing with median mean heart dose less than 1 Gy (RBE). CONCLUSION: With close to three years of median follow-up, post-mastectomy proton radiation has shown excellent locoregional control rates and favorable toxicity profile. Long-term adverse effect of heart-sparing radiation will require longer follow-up time and randomized clinical trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Luo L, Cuaron J, Braunstein L, et al. Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy. Radiother Oncol. 2018. PMID: 30414757. doi:10.1016/j.radonc.2018.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。